Halozyme Therapeutics (NASDAQ: HALO) reported Q2 EPS of $1.54, $0.30 better than the analyst estimate of $1.24. Revenue for the quarter came in at $326 million versus the consensus estimate of $286.01 million.

GUIDANCE:

Halozyme Therapeutics sees FY2025 EPS of $6.00-$6.40, versus the consensus of $5.40. Halozyme Therapeutics sees FY2025 revenue of $1.27-1.35 billion, versus the consensus of $1.25 billion.

For earnings history and earnings-related data on Halozyme Therapeutics (HALO) click here.